全腹调强放疗应用于铂类耐药型复发上皮性卵巢癌的临床疗效及对各肿瘤标志物表达的影响

Efficacy of clinical whole abdominal intensity modulated radiotherapy in platinum-resistant recurrent epithelial ovarian cancer and its influence on the expression of tumor markers

目的探讨铂类耐药型复发上皮性卵巢癌(recurrent epithelial ovarian cancer,REOC)患者应用全腹调强放疗的近远期疗效以及对糖类抗原125(carbohydrate antigen 125,CA125)、癌胚抗原(carcinoembryonic antigen,CEA)及糖类抗原153(carbohydrate antigen 153,CA153)的影响。方法回顾性队列研究,选取2020年6月—2022年6月郑州大学第一附属医院收治的101例上皮性卵巢癌患者,分析入组者临床资料,以复发后不同治疗方案分组。对照组52例行单纯化疗,研究组49例在对照组基础上行全腹调强放疗,对比两组近期疗效、远期疗效、肿瘤标志物及不良反应。结果研究组疾病控制率(75.51%)高于对照组(55.77%),组间差异有统计学意义(P<0.05);研究组无进展生存期(progression-free survival,PFS)、总生存期(overall survival,OS)时间长于对照组,差异有统计学意义(P<0.05);研究组治疗后CA125、CEA及CA153等肿瘤标志物水平[(36.49±4.61)U/mL、(4.54±1.34)U/mL、(30.12±3.21)U/mL]明显低于对照组[(58.46±6.82)U/mL、(8.42±1.93)U/mL、(42.16±6.28)U/mL],组间差异有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(26.92%vs 36.73%)(P>0.05)。结论铂类耐药型REOC患者应用全腹调强放疗治疗,可下调肿瘤标志物表达,提高近期疗效,有利于延长患者生存时间,且不会增加不良反应。

Objective To investigate the short-term and long-term therapeutic efficacy of whole abdominal intensity modulated radiotherapy in patients with recurrent epithelial ovarian cancer(REOC)and its impact on the levels of carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and carbohydrate antigen 153(CA153).Methods Retrospective cohort study,selected the clinical data of 101 patients with epithelial ovarian cancer treated in the First Affiliated Hospital of Zhengzhou University from June 2020 to June 2022 were retrospectively analyzed,and the patients were divided into different treatment plans after recurrence.52 patients in the control group received chemotherapy alone,and 49 patients in the study group received whole abdominal intensity modulated radiotherapy based on the control group.The adverse reactions,tumor markers,long-term efficacy,and short-term efficacy of the two groups were compared.Results The disease control rate of the study group(75.51%)was higher than that of the control group(55.77%),and the difference was statistically significant(P<0.05);progression-free survival(PFS)and overall survival(OS)of the study group were longer than those of the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of tumor markers such as CA125,CEA and CA153 in the study group[(36.49±4.61)U/mL,(4.54±1.34)U/mL,(30.12±3.21)U/mL]were significantly lower than those in the control group[(58.46±6.82)U/mL,(8.42±1.93)U/mL,(42.16±6.28)U/mL],and the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(26.92%vs 36.73%)(P>0.05).Conclusion Whole abdominal intensity modulated radiotherapy can down-regulate the expression of tumor markers,improve the short-term efficacy,and prolong the survival time of patients with platinum-resistant REOC without increasing adverse reactions.